Markets
Borrow
Earn
Invest
Private
Security
Newsroom
More
Log In
Sign Up
Markets
Market Overview
Indices and commodities.
Digital Credit
Bitcoin treasury preferreds.
AI Stocks
The artificial intelligence theme.
Bitcoin Treasuries
Companies holding bitcoin.
Economy
Sectors, global markets and rates.
Popular Portfolios
13F filings, smart money.
Borrow
Borrow
Borrow USDT or USDC against your BTC without giving it up.
ReFi
Switch your bitcoin-backed loan and pay less interest.
Earn
Carry Trade
Borrow, invest, keep the spread.
Stock Dividends
Dividends from tokenized equities.
Invest
Private
Security
Newsroom
More
Company
About Us
Our leadership team, mission, and investors.
Whitepaper
Vision, purpose, and architecture behind Roxom.
Legal
Terms, privacy, and disclosures.
Resources
Help Center
Guides, FAQs & support.
Rulebook
Trading logic, platform rules, and fundamentals.
API Docs
Connect, authenticate, and build with our API.
Status
Current platform health and incidents.
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
1 BTC
=
- USD
BTC
SATS
Loading market data...
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
CU
Curanex Pharmaceuticals Inc Common Stock
CURX
Mkt Cap
$7.3M
Volume
10.53K
Next Earnings
November 13th
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
CU
CURX
CU
Curanex Pharmaceuticals Inc Common Stock
CURX
News
·
CURX Investors Have Opportunity to Join Curanex Pharmaceuticals Inc Fraud Investigation with the Schall Law Firm
Mkt Cap
$7.2M
Volume
10.53K
Next Earnings
November 13th
Chart
Financials
Earnings
News
About
Insider
Filings
CURX Investors Have Opportunity to Join Curanex Pharmaceuticals Inc Fraud Investigation with the Schall Law Firm
The Schall Law Firm is investigating Curanex Pharmaceuticals Inc. (NASDAQ: CURX) for potential securities law violations, alleging the company issued false or misleading statements and failed to disclose material information to investors. The firm is seeking shareholders who suffered losses to participate in the investigation.
GlobeNewswire Inc. · May 1, 2026
Curanex Provides Business Update in Connection with 2025 Annual Report as Phyto-N Advances Toward Planned IND Submission
Curanex Pharmaceuticals announced significant progress on its lead asset Phyto-N, completing a pilot-scale GMP batch and dose-range finding toxicology studies with no significant adverse findings. The company maintains its target for IND submission in Q4 2026 for ulcerative colitis treatment and plans Phase 1 clinical development in Australia. The company has sufficient funding for at least the next 12 months to support development objectives.
GlobeNewswire Inc. · Mar 30, 2026
Curanex Pharmaceuticals Inc. Announces Exercise of the Over-Allotment Option by Underwriters
Curanex Pharmaceuticals completed its initial public offering by having Dominari Securities fully exercise the over-allotment option, raising an additional $2.25 million and bringing total gross proceeds to $17.25 million through the issuance of 4,312,500 shares at $4.00 per share.
GlobeNewswire Inc. · Sep 12, 2025
Curanex Pharmaceuticals Inc. Announces Closing of its Initial Public Offering
Curanex Pharmaceuticals completed its initial public offering of 3,750,000 shares at $4.00 per share, raising $15 million. The company, focused on botanical drugs for inflammatory diseases, began trading on Nasdaq under ticker CURX.
GlobeNewswire Inc. · Aug 27, 2025
Holdings
Open Orders (0)
Positions (0)
Order History
Dividends
Transfers
Log In
to start trading
CU
CURX
Curanex Pharmaceuticals Inc Common Stock
Buy
Sell
Market
Limit
Soon
CURX
25%
50%
75%
Max
Pay with
—
Start Trading
Available Balance
0.00
Your Position
You don't own any CURX yet.
Related Tickers
Earnings